GlassScriptPhysician profile
Thuy Thanh Pham
NPI 1740280189
$2,290.19
in general payments reported to CMS, 2019-2025
23 companies · $335 in 2025
The $335 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $213 · 2021: $156 · 2022: $226 · 2023: $628 · 2024: $452 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.50 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $431.82 | 2021-2025 | Qelbree, Qelbree |
| Abbott Laboratories | $287.03 | 2020-2024 | Coroflow |
| Ironshore Pharmaceuticals INC. | $262.65 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $226.16 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $202.53 | 2023-2025 | Azstarys |
| Sanofi Pasteur INC. | $88.71 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.05 | 2023 | Lifevest |
| Cranial Technologies, INC | $87.46 | 2019-2025 | Doc Band |
| Sobi, INC | $75.91 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $68.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $67.64 | 2023-2024 | Flumist Quadrivalent |
| Pfizer INC. | $56.13 | 2019-2023 | |
| Phadia US INC. | $55.61 | 2022-2023 | Immunocap |
| Biotronik INC. | $53.87 | 2022 | |
| Tris Pharma INC | $53.75 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $39.09 | 2020 | |
| Cipher Pharmaceuticals US LLC | $37.05 | 2025 | Spinosad, Natroba |
| Ars Pharmaceuticals Operations, INC. | $24.82 | 2025 | Neffy |
| Lantheus Medical Imaging, INC. | $18.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.04 | 2020 | |
| Hologic Sales and Service, LLC | $16.57 | 2023 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Kowa Pharmaceuticals America, INC. | $15.47 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $14.78 | 2024 | Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.